Summary of HCKT Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $72.2 million, a decrease of 7% year-over-year, slightly below guidance.

Adjusted EPS: $0.37, at the midpoint of guidance, compared to $0.43 in Q3 2024.

GAAP Net Income: $2.5 million ($0.09 per share), down from $8.6 million ($0.31 per share) in the prior year.

Adjusted Gross Margin: 42.6%, down from 43.2% year-over-year.

Consultant Headcount: Reduced to 1,317 from 1,382 in the previous quarter, reflecting restructuring to align with demand.

Cash Flow: Generated $11.4 million from operations, with cash balances of $13.9 million at quarter-end.

Stock Repurchase: Announced a $40 million Dutch tender offer to buy back shares.

2Strategic Updates and Business Highlights

AI XPLR Version 4: Launched in September, received positive feedback for its game-changing capabilities, enhancing GenAI solutions.

Strategic Alliances: Initiated partnerships, including a notable alliance with Celonis for process intelligence integration into AI XPLR.

GenAI Growth: Strong performance in GenAI consulting and implementation, expected to drive future revenue growth.

New Initiatives: Launched the GenAI premium program and expanded executive advisory services through the acquisition of Spend Matters.

3Forward Guidance and Outlook

Q4 Revenue Guidance: Estimated between $69.5 million to $71 million, reflecting continued weakness in Oracle Solutions and expected declines in SAP Solutions.

Adjusted EPS Guidance: Expected to be in the range of $0.38 to $0.40.

Long-term Outlook: Anticipates continued growth in GenAI-related revenues, with a focus on expanding recurring revenue streams and strategic partnerships.

4Bad News, Challenges, or Points of Concern

Revenue Declines: Notable decreases in Oracle Solutions (down 25%) and overall revenues, attributed to prolonged client decision-making and the expiration of key contracts.

Headcount Reduction: Staff reductions to align with current demand and expected productivity improvements, raising concerns about resource availability.

Market Conditions: Economic volatility and client hesitance to commit to spending in 2025 due to uncertainties, impacting decision-making processes.

5Notable Q&A Insights

Strategic Alliances: CEO Ted Fernandez expressed optimism about securing major partnerships, highlighting the enhanced capabilities of AI XPLR Version 4 as a key factor.

Licensing Progress: Anticipated licensing of AI XPLR Version 4 by late Q4 2025, with expectations for significant client interest.

Decision-Making Trends: Clients are cautious about 2025 spending due to economic factors, but there is a growing interest in investing in GenAI initiatives.

Competitive Positioning: The company believes its unique capabilities in GenAI and process automation differentiate it from competitors, with positive feedback from potential partners. Overall, while HCKT faces challenges in revenue growth and market conditions, strategic initiatives in AI and partnerships position it for potential future growth.